Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.6752W HIGH $22.88
Volume
126.50 K
Value Traded
2.66 M
Short % Float
3.04%
+0.68%Week
-7.9%1 Month
+23.27%3 Month
+30.28%6 Month
-65.71%5 Year
+325.14%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
257.35 M
EPS (TTM)
-0.28
P/E Ratio
-
Ent. Value
218.94 M
Total Shares
13.38 M
Float Shares
12.54 M
Insiders
6.28%
Institutions
91.71%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ANIK Catalyst Timeline
Dated clinical, regulatory and corporate events for Anika Therapeutics Inc.
Past FDA Catalysts and PDUFA Decisions
How ANIK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D32 / 100
Pipeline Score
$73M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
0.3x
rNPV / MCap
Top 62%
Micro Cap(rank 408 of 658)
Percentile Rank
Anika Therapeutics Inc. faces pipeline headwinds (32/100), with $292M risk-adjusted pipeline value, led by Cingal in Osteoarthritis of the Knee (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cingal Small moleculeCompletedNCT03390036 | Knee Osteoarthritis | Phase 3 | COMPLETED | 1,333 | Jul 30, 2018 |
Clinical Trial Results
Readouts, endpoints and source filings for every ANIK program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Hyalofast | articular cartilage defects in the knee | Phase 3 | 2025-11-05 | KOOS Pain difference: 8.11%; IKDC Function difference: 4.84%; Hyalofast KOOS Pain improvement: 4.54 points; Hyalofast IKDC improvement: 2.19 points; Hyalofast observed data improvement: 23.37%Read More | Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III StudyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Fischetti Gary PDirector | Buy | 1,000 54,015 held | $20.32 | 08/04/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ANIK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Opaleye Management Inc. | 1.3 % | 6.23 M | 588.80 K | 49.06% ( 193.80 K) |
ANIK Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ANIK ranks across every disease it competes in
Competitive Position is a premium feature
See how ANIK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialANIK News
ANIKAnika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
Anika Therapeutics, Inc. will release its second quarter 2026 financial results on July 29, 2026, before market opening. A conference call to discuss these results will follow at 8:30 a.m. ET. Investors can access the call via phone or a live audio webcast on Anika's website.
Read more →ANIKSummer Activities and Foods That Support Joint Health
The article discusses how summer activities and foods can support joint health. It highlights low-impact exercises such as swimming, cycling, and gentle yoga that are beneficial for joint mobility. Additionally, it emphasizes the importance of incorporating anti-inflammatory foods like omega-3 fatty acids and berries into the diet. Small, consistent changes can lead to significant improvements in joint health.
Read more →ANIKUnexplained Bone Pain? Understanding Insufficiency Fractures and Tactoset
The article discusses insufficiency fractures, which are small cracks in the bone caused by gradual stress rather than a single incident. It highlights the challenges in diagnosing these fractures, as they often do not appear on standard X-rays. Tactoset, a treatment made from calcium phosphate and hyaluronic acid, is introduced as a minimally invasive option to support healing in chronic cases. The article emphasizes the importance of consulting with a doctor for persistent bone pain.
Read more →ANIKOsteoarthritis and Inflammation: Understanding What’s Happening Inside the Joint
The article discusses the role of joint inflammation in osteoarthritis, emphasizing its impact on joint health and movement. It explains how chronic inflammation can lead to pain and reduced mobility, while also highlighting lifestyle changes that can help manage inflammation. Treatments based on hyaluronic acid are presented as a potential solution for improving joint function.
Read more →ANIKAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. has announced the granting of restricted stock units (RSUs) to a newly hired non-executive employee as part of its 2021 Inducement Plan. This grant includes a total of 3,360 shares, which will vest in three equal installments over the next three years, contingent on the employee's continuous service. This action was taken to incentivize the new hire and is compliant with Nasdaq Listing Rule 5635(c)(4). Anika's focus remains on osteoarthritis pain management and regenerative solutions.
Read more →ANIKWhat Is <span class="notranslate" translate="no">Cingal</span>? A Proven Joint Injection for Osteoarthritis Pain
Cingal is a single-injection treatment for knee osteoarthritis pain, combining hyaluronic acid and a corticosteroid for effective relief. With over a million injections performed globally, it provides rapid and sustained pain relief. However, it is not currently approved in the U.S., and patients should consult their doctors regarding its availability.
Read more →ANIKCan the Body Heal Joint Tissue on its Own?
The article discusses the challenges of healing joint tissues, particularly tendons and cartilage, due to their limited blood supply. It highlights the role of regenerative medicine and treatments like hyaluronic acid and scaffolds in supporting the healing process. The Integrity implant and Hyalofast scaffold are mentioned as potential options for tendon and cartilage injuries, respectively.
Read more →ANIKThe Science of Healing: How Biologic Scaffolds Support Your Body’s Recovery
The article discusses the advancements in orthopedic care through biologic scaffolds, which support the body’s healing process by providing a structure for tissue regeneration. These scaffolds can be made from natural or synthetic materials and are used in various orthopedic surgeries. Notable products like Hyaff and Integrity are highlighted for their effectiveness in cartilage and tendon repair, respectively.
Read more →ANIK▼ -18.8%on this newsshared move
Anika Reports First Quarter 2026 Financial Results
Anika Therapeutics reported a 13% increase in total revenue for Q1 2026, reaching $29.6 million, driven by strong performance in both Commercial and OEM Channels. The company achieved a gross margin of 64.2%, up from 56.1% the previous year, and reported an adjusted EBITDA of $4.3 million. However, operating expenses rose significantly due to severance costs, and the company faces ongoing challenges with FDA approvals.
Read more →ANIKAnika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
Anika Therapeutics, Inc. will announce its first quarter 2026 financial results on April 29, 2026. The announcement will be followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the call via phone or a live audio webcast on Anika's website.
Read more →ANIKTendon Repair: How The <span class="notranslate" translate="no">Integrity</span> Implant Supports Your Return to Active Living
The article discusses the challenges of tendon injuries and introduces Anika's Integrity Implant as a solution for enhancing healing. This biologic scaffold supports tendon repair by creating an optimal healing environment, utilizing hyaluronic acid without animal-derived materials. The Integrity Implant aims to improve recovery times and outcomes for patients with tendon injuries, allowing them to return to active lifestyles more effectively.
Read more →ANIKSpring Into Motion: The Best Season to Get Your Joints Moving
The article emphasizes the importance of keeping joints active, especially during spring when outdoor conditions are favorable. It suggests various low-impact activities such as walking, cycling, swimming, and yoga that can help maintain joint health. The piece encourages readers to consult healthcare professionals before starting new activities and to listen to their bodies while exercising. Overall, it promotes a proactive approach to joint care during the spring season.
Read more →ANIKRepairing Cartilage Injuries: How <span class="notranslate" translate="no">Hyalofast</span> Works in the Knee
Hyalofast is a regenerative medicine solution designed to repair cartilage injuries in the knee. Made from hyaluronic acid, it acts as a scaffold to support the body's natural healing processes. Clinical studies indicate that it leads to durable cartilage regeneration and improved knee function over time. The procedure is minimally invasive and can be performed in a single stage.
Read more →ANIK▲ +16.9%on this news· ran to +32% by day 3
Anika Reports Fourth Quarter and Full Year 2025 Financial Results
Anika Therapeutics reported its financial results for Q4 and the full year 2025, showing a 22% increase in Commercial Channel revenue. Despite a 6% decrease in total revenue year-over-year, the company achieved positive operating cash flow and expanded gross margins. Anika is focused on advancing its product portfolio and has reaffirmed its guidance for 2026.
Read more →ANIKAnika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
Anika Therapeutics, Inc. has announced that its President and CEO, Steve Griffin, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on March 2, 2026. The company will also hold one-on-one meetings with investors during the event. The presentation will be accessible via live webcast and archived on Anika’s website for 30 days. Anika focuses on advancements in orthopedic care, particularly in the fields of osteoarthritis pain management and regenerative solutions.
Read more →ANIKAnika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
Anika Therapeutics, Inc. will announce its fourth quarter and year-end 2025 financial results on February 26, 2026. Before the market opens, stakeholders can access a conference call at 8:30 a.m. ET to discuss these results and business highlights. Anika, a global joint preservation company headquartered outside Boston, emphasizes advancements in minimally invasive orthopedic care, particularly in pain management and regenerative solutions.
Read more →ANIKLumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors
Lumicell, Inc. has appointed Cheryl R. Blanchard, Ph.D., to its Board of Directors. Dr. Blanchard, a seasoned leader with over 30 years of experience in biotech and medtech, previously served as President and CEO of Anika Therapeutics. Her expertise is anticipated to drive Lumicell's growth and enhance its innovative cancer detection technologies.
Read more →ANIKAnika Therapeutics Announces Leadership Transition
Anika Therapeutics has announced a leadership change as Stephen Griffin will take over as President and CEO on February 1, 2026, succeeding Cheryl Blanchard, who transitions to Executive Chair. Griffin, currently the CFO and COO, holds a strong track record in strategic transformation and operational excellence. Blanchard emphasizes the company's readiness for this change as it shifts focus towards future growth opportunities, reinforcing Anika's role in osteoarthritis pain management. The leadership transition is expected to maintain momentum in the company's strategic initiatives and profitability.
Read more →About Anika Therapeutics Inc.
Headquarters32 WIGGINS AVENUE, BEDFORD, MA, 01730
Founded1992
BIOPHARMAWATCH ELITE PLUS
Trade the next ANIK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime